New Therapies of Neovascular AMD beyond Anti-VEGF Injections

• Main Authors: Greggory M. Gahn, Arshad M. Khanani
• Format: Article
• Language: English
• Published: MDPI AG 2018-03-01
• Series: Vision
• Subjects: age-related macular degeneration; Tie2; anti-VEGF; RG7716; ranibizumab
• Online Access: http://www.mdpi.com/2411-5150/2/1/15

Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through intravitreal injections. Recent studies have demonstrated that the tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (Tie2) pathway also plays a critical role in angiogenesis and vascular stability. Additionally, newly developed treatment delivery systems have been designed to greatly reduce the frequency of injections. In targeting the Tie2 pathway and utilizing a sustained release delivery system, patients may experience improved visual outcomes and a reduced burden of treatment.